HealthcareAug 11, 2026

GW Pharmaceuticals plc

Company Profile Analysis

Book Demo Subscribe Now

GW Pharmaceuticals plc - Healthcare showcase

Year Founded & Workforce

1997-12-31

1,000 Employees

Industry

Healthcare

Services

GW Pharmaceuticals plc Overview

Company Headquarter: Cambridge, UK

Founded: 1998

Workforce: ~1000

Company Working: GW Pharmaceuticals plc is a world leader in the development of plant-derived cannabinoid therapeutics. The company has a strong presence in the UK and the US. It also has a presence in the EU5 countries (France, Germany, Italy, Spain, and the UK), the Netherlands, and Switzerland, among others. It has ties with leading cannabinoid scientists across the globe. It offers a wide range of novel cannabinoid molecules in several distinct therapeutic areas, including autism, epilepsy, and schizophrenia. The company is focusing on offering cannabinoid-based prescription medicines to patients. In May 2021, GW Pharmaceuticals plc became subsidiary of Jazz Pharmaceuticals (Ireland), a leader in the science, development, and commercialization of cannabinoid-based prescription medicines.

Strategy

GW Pharmaceuticals plc focuses on developing life-changing medicines for severe diseases that have limited or no therapeutic options. It is working with cannabinoid scientists around the globe to develop advanced products. It is making various partnerships in the region for future growth. Furthermore, the corporation works aggressively with other companies to incorporate advances and expand product reach.

Company Snapshot

1,000

Employees

1997-12-31

Founded

SWOT Analysis

Strengths

Strong presence in US and UK
Trained workforce
Focus on developing innovative products

Weaknesses

Limited commercialization of products
Operational failures

Opportunities

Strategic initiatives
Legalization of cannabis for medical use in many countries

Threats

Changing political leaderships in some regions
Strong rules and regulations in some countries

Key Developments

Date	Approach	Development
August 2021	Product Approval	GW Pharmaceuticals plc received approval from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for Epidiolex. This product can be used in the treatment of seizures associated with tuberous sclerosis complex (TSC).
June 2018	Product Approval	GW Pharmaceuticals plc received FDA approval for its leading product, Epidiolex to launch in the US, a liquid formulation of highly purified cannabidiol.

Product Offering

GW Pharmaceuticals plc
- Medical Cannabis Market

A plan for every need

Forecast+

Get unlimited access to forecasts, charts, and company data across every research report on Wantstats.

USD49/mo

About the Author

Wantstats Research Team

Wantstats' research desk profiles GW Pharmaceuticals plc as part of our ongoing coverage of the Healthcare sector, drawing on public company data, filings, and market intelligence.

Powering the world's best teams.
From next-gen startups to established enterprises.

See our work in action

Start your data driven journey with us!

Book a Demo Now

What our clients say

Trusted by forward-thinking businesses
for data-driven intelligence

Noah Malgeri

Co-Founder, Mojave Rail Fabrication Limited

This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.

Michael Robert

Manager, JavolVision

Thanks, I am so happy that we worked together. Maybe we still can work together in the future.

Joseph Aguayo

Sales Operations & Pricing Manager, Intel

Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.

Bong Lau

Sales Leader, Bamberg

We bought your "2025 report" in 2020. Everything is fine and very good.

Peter Groot Koerkamp

Account and Business Manager, EFS-Holland BV

Thanks for sending the report it gives us a good global view of the Betaïne market.

Younghwan Choi

Senior Retail Manager, LG Chem

We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.

Mark Irwin

Management Consultant, Level 21

I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.

Rob Kooiker

Group Product Manager HVAC & Fire Protection GMA, Rockwool

I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!

Jason Lee

R&D Director, Seojin

Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.

Akif Moroglu

Strategy & Business Development Director, Dogan Holding

We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.

Noah Malgeri

Co-Founder, Mojave Rail Fabrication Limited

This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.

Michael Robert

Manager, JavolVision

Thanks, I am so happy that we worked together. Maybe we still can work together in the future.

Joseph Aguayo

Sales Operations & Pricing Manager, Intel

Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.

Bong Lau

Sales Leader, Bamberg

We bought your "2025 report" in 2020. Everything is fine and very good.

Peter Groot Koerkamp

Account and Business Manager, EFS-Holland BV

Thanks for sending the report it gives us a good global view of the Betaïne market.

Younghwan Choi

Senior Retail Manager, LG Chem

We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.

Mark Irwin

Management Consultant, Level 21

I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.

Rob Kooiker

Group Product Manager HVAC & Fire Protection GMA, Rockwool

I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!

Jason Lee

R&D Director, Seojin

Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.

Akif Moroglu

Strategy & Business Development Director, Dogan Holding

We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.

GW Pharmaceuticals plc

Company Headquarter: Cambridge, UK Founded: 1998 Workforce: ~1000 Company Working: GW Pharmaceuticals plc is a world leader in the development of plant-derived cannabinoid therapeutics. The company has a strong presence in the UK and the US. It also has a presence in the EU5 countries (France, Germany, Italy, Spain, and the UK), the Netherlands, and Switzerland, among others. It has ties with leading cannabinoid scientists across the globe. It offers a wide range of novel cannabinoid molecules in several distinct therapeutic areas, including autism, epilepsy, and schizophrenia. The company is focusing on offering cannabinoid-based prescription medicines to patients. In May 2021, GW Pharmaceuticals plc became subsidiary of Jazz Pharmaceuticals (Ireland), a leader in the science, development, and commercialization of cannabinoid-based prescription medicines.

Starting from

$4,950